Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.

ABSTRACT:

Background/aims

The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.

Methods

Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022-2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with th

SUBMITTER: Wu M 

PROVIDER: S-EPMC12016657 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature